Quick Answer
Tevogen Bio Holdings Inc. reported Stockholders Equity of -$8.23 million for the year ending 2025.
- Tevogen Bio Holdings Inc. showed a decrease of -23.4% in Stockholders Equity from 2024 to 2025.
- This data is from Tevogen Bio Holdings Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2021 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $13.7 thousand | Q3 2021: $13.6 thousand | Q1 2022: -$14.25 million | Q2 2022: -$14.05 million | Q3 2022: -$14.66 million | Q1 2023: -$64.71 million | Q2 2023: -$86.89 million | Q3 2023: -$90.80 million | Q1 2024: -$5.80 million | Q2 2024: -$7.66 million | Q3 2024: -$6.19 million | Q1 2025: -$7.72 million | Q2 2025: -$9.48 million | Q3 2025: -$7.82 million.
- Historical annual values: Fiscal year 2025: -$8.23 million | Fiscal year 2024: -$6.67 million | Fiscal year 2023: -$94.43 million | Fiscal year 2022: -$33.95 million | Fiscal year 2021: -$14.23 million | Fiscal year 2021: $0.00.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: